1
Clinical Trials associated with LY-3981314A Single-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3981314 in Healthy Participants
The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body.
The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
100 Clinical Results associated with LY-3981314
100 Translational Medicine associated with LY-3981314
100 Patents (Medical) associated with LY-3981314
100 Deals associated with LY-3981314